

represents a significant treatment advance for AD patients (Ariëns *et al.*, Ther. Adv. Chronic Dis. 9:159-70 (2018)). Nevertheless, AD exhibits biological and clinical heterogeneity (Muraro *et al.*, J. Allergy Clin. Immunol. 137:1347-58 (2016), Czarnowicki *et al.*, J. Allergy Clin. Immunol. 143:1-11 (2019)), where even novel therapeutic agents such as dupilumab, have displayed variable efficacy responses in subjects with moderate to severe AD. Results from dupilumab's Phase 3 registrational program (SOLO 1 and SOLO 2), demonstrated efficacy in treating patients moderate to severe AD. However less than half of the subjects (38% to 36% respectively) enrolled in the pivotal studies experienced a reduction of Investigators' Global Assessment (IGA) to either 1 (almost clear) or 0 (clear) after 16 weeks of treatment. These data highlight some of the challenges physicians face in treating patients with moderate to severe disease, as even with advanced therapeutic agents such as dupilumab, a majority of the patients do not have adequate control of their disease. As such, there remains a high unmet need for novel targeted therapies to improve patient outcomes, lessen disease burden, and further expand the current treatment paradigms available for AD patients with more advanced disease. (Simpson *et al.* (2017); Simpson *et al.*, N. Eng. J. Med. 375:2335-48 (2016)).

SUMMARY

One example is for a method of treating atopic dermatitis comprising administering to a subject in need thereof a therapeutically effective amount of an anti-IL-13 antibody, or antigen binding fragment thereof, thereby treating atopic dermatitis in the subject. In some examples, the anti-IL-13 antibody comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein the anti-IL-13 antibody comprises at least one of: (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2; (b) CDR-H2 comprising residues 52-67 of SEQ ID NO:2; (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2; (d) CDR-L1 comprising residues 24-34 of SEQ ID NO:3; (e) CDR-L2 comprising residues 50-56 of SEQ ID NO:3; or (f) CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, and CDR-H3

comprising residues 100-112 of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, CDR-H3 comprising residues 100-112 of SEQ ID NO:2, CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises an L240A mutation. In some examples, the anti-IL-13 antibody comprises an L241A mutation. In some examples, the anti-IL-13 antibody comprises an L240A mutation and L241A mutation. In some examples, the anti-IL-13 antibody is cendakimab. In some examples, the anti-IL-13 antibody is administered subcutaneously. In some examples, the anti-IL-13 antibody is administered at a dosage of about 100 mg to about 1000 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 200 mg to about 900 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 300 mg to about 800 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 360 mg to about 720 mg to the subject. In some examples, the atopic dermatitis is a moderate atopic dermatitis. In some examples, the atopic dermatitis is a severe atopic dermatitis. In some examples, the atopic dermatitis is a moderate to severe atopic dermatitis.

Another aspect is for an anti-IL-13 antibody, or antigen binding fragment thereof, for use in therapy, wherein the anti-IL-13 antibody, or antigen binding fragment thereof, comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2; (b) CDR-H2 comprising residues 52-67 of SEQ ID NO:2; (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2; (d) CDR-L1 comprising residues 24-34 of SEQ ID NO:3; (e) CDR-L2 comprising residues 50-56 of SEQ ID NO:3; and (f) CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In one example, the present disclosure provides an anti-IL-13 antibody, or antigen binding fragment thereof, for use in the treatment of atopic dermatitis. In some examples, the anti-IL-13 antibody comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-

H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein the anti-IL-13 antibody comprises at least one of: (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2; (b) CDR-H2 comprising residues 52-67 of SEQ ID NO:2; (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2; (d) CDR-L1 comprising residues 24-34 of SEQ ID NO:3; (e) CDR-L2 comprising residues 50-56 of SEQ ID NO:3; or (f) CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, and CDR-H3 comprising residues 100-112 of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, CDR-H3 comprising residues 100-112 of SEQ ID NO:2, CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises an L240A mutation. In some examples, the anti-IL-13 antibody comprises an L241A mutation. In some examples, the anti-IL-13 antibody comprises an L240A mutation and L241A mutation. In some examples, the anti-IL-13 antibody is cendakimab. In some examples, the anti-IL-13 antibody is administered subcutaneously. In some examples, the anti-IL-13 antibody is administered at a dosage of about 100 mg to about 1000 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 200 mg to about 900 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 300 mg to about 800 mg to the subject. In some examples, the anti-IL-13 antibody is

administered at a dosage of about 360 mg to about 720 mg to the subject. In some examples, the atopic dermatitis is a moderate atopic dermatitis. In some examples, the atopic dermatitis is a severe atopic dermatitis. In some examples, the atopic dermatitis is a moderate to severe atopic dermatitis.

5 A further aspect is for the use of an anti-IL-13 antibody, or antigen binding fragment thereof, in the manufacture of a medicament for the treatment of atopic dermatitis, wherein the anti-IL-13 antibody, or antigen binding fragment thereof, comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2; (b) CDR-H2 comprising
10 residues 52-67 of SEQ ID NO:2; (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2; (d) CDR-L1 comprising residues 24-34 of SEQ ID NO:3; (e) CDR-L2 comprising residues 50-56 of SEQ ID NO:3; and (f) CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In another example, the present disclosure provides the use of an anti-IL-13 antibody, or antigen binding fragment thereof, for the manufacture of a medicament for the treatment of
15 atopic dermatitis. In some examples, the anti-IL-13 antibody comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein the anti-IL-13 antibody comprises at least one of: (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2; (b) CDR-H2 comprising residues 52-67 of SEQ ID NO:2; (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2; (d) CDR-L1 comprising residues
20 24-34 of SEQ ID NO:3; (e) CDR-L2 comprising residues 50-56 of SEQ ID NO:3; or (f) CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, and CDR-H3 comprising residues 100-112 of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises CDR-L1 comprising residues
25 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, CDR-H3 comprising residues 100-112 of SEQ ID NO:2, CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of
30 SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain
35 comprising the amino acid sequence of SEQ ID NO:2 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises an L240A mutation. In some examples, the anti-IL-13 antibody comprises an L241A mutation. In some examples, the anti-IL-13 antibody

comprises an L240A mutation and L241A mutation. In some examples, the anti-IL-13 antibody is cendakimab. In some examples, the anti-IL-13 antibody is formulated for subcutaneous administration. In some examples, the anti-IL-13 antibody is formulated for a dosage of about 100 mg to about 1000 mg. In some examples, the anti-IL-13 antibody is formulated for a dosage of about 200 mg to about 900 mg. In some examples, the anti-IL-13 antibody is formulated for a dosage of about 300 mg to about 800 mg. In some examples, the anti-IL-13 antibody is formulated for a dosage of about 360 mg to about 720 mg to the subject. In some examples, the atopic dermatitis is a moderate atopic dermatitis. In some examples, the atopic dermatitis is a severe atopic dermatitis. In some examples, the atopic dermatitis is a moderate to severe atopic dermatitis.

An additional example is for a method of reducing incidence of atopic dermatitis administering to a subject in need thereof a therapeutically effective amount of an anti-IL-13 antibody, or antigen binding fragment thereof, thereby reducing incidence of atopic dermatitis in the subject. In some examples, the anti-IL-13 antibody comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein the anti-IL-13 antibody comprises at least one of: (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2; (b) CDR-H2 comprising residues 52-67 of SEQ ID NO:2; (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2; (d) CDR-L1 comprising residues 24-34 of SEQ ID NO:3; (e) CDR-L2 comprising residues 50-56 of SEQ ID NO:3; or (f) CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, and CDR-H3 comprising residues 100-112 of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, CDR-H3 comprising residues 100-112 of SEQ ID NO:2, CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some

examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises an L240A mutation. In some examples, the anti-IL-13 antibody comprises an L241A mutation. In some examples, the anti-IL-13 antibody comprises an L240A mutation and L241A mutation. In some examples, the anti-IL-13 antibody is cendakimab. In some examples, the anti-IL-13 antibody is administered subcutaneously. In some examples, the anti-IL-13 antibody is administered at a dosage of about 100 mg to about 1000 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 200 mg to about 900 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 300 mg to about 800 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 360 mg to about 720 mg to the subject. In some examples, the atopic dermatitis is a moderate atopic dermatitis. In some examples, the atopic dermatitis is a severe atopic dermatitis. In some examples, the atopic dermatitis is a moderate to severe atopic dermatitis.

Another example is for a method of treating atopic dermatitis comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition that prevents IL-13 interaction with IL-13R α 1 and IL-13R α 2. In some examples, the pharmaceutical composition comprises an anti-IL-13 antibody, or antigen binding fragment thereof, and in some examples, the anti-IL-13 antibody comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein the anti-IL-13 antibody comprises at least one of: (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2; (b) CDR-H2 comprising residues 52-67 of SEQ ID NO:2; (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2; (d) CDR-L1 comprising residues 24-34 of SEQ ID NO:3; (e) CDR-L2 comprising residues 50-56 of SEQ ID NO:3; or (f) CDR-L3 comprising residues

89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, and CDR-H3 comprising residues 100-112 of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, CDR-H3 comprising residues 100-112 of SEQ ID NO:2, CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises an L240A mutation. In some examples, the anti-IL-13 antibody comprises an L241A mutation. In some examples, the anti-IL-13 antibody comprises an L240A mutation and L241A mutation. In some examples, the anti-IL-13 antibody is cendakimab. In some examples, the anti-IL-13 antibody is administered subcutaneously. In some examples, the anti-IL-13 antibody is administered at a dosage of about 100 mg to about 1000 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 200 mg to about 900 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 300 mg to about 800 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 360 mg to about 720 mg to the subject. In some examples, the atopic dermatitis is a moderate atopic dermatitis. In some examples, the atopic dermatitis is a severe atopic dermatitis. In some examples, the atopic dermatitis is a moderate to severe atopic dermatitis.

A further example is for a method of determining the effectiveness of treating atopic dermatitis in a subject in need thereof comprising (a) administering to the subject a therapeutically effective amount of an anti-IL-13 antibody, or antigen binding fragment thereof, thereby treating atopic dermatitis in the subject; and (b) determining whether the subject exhibits an increase or decrease in the level of one or more of peripheral blood eosinophils, IgE, lactate dehydrogenase, IL-13, IL-22, TARC, and/or PARC from a baseline level of peripheral blood eosinophils, IgE, lactate dehydrogenase, IL-13, IL-22, TARC, and/or PARC in the subject prior to the administering of step (a). In some examples, the anti-IL-13 antibody comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein the anti-IL-13 antibody comprises at least one of: (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2; (b) CDR-H2 comprising residues 52-67 of SEQ ID NO:2; (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2; (d) CDR-L1 comprising residues 24-34 of SEQ ID NO:3; (e) CDR-L2 comprising residues 50-56 of SEQ ID NO:3; or (f) CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, and CDR-H3 comprising residues 100-112 of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, CDR-H3 comprising residues 100-112 of SEQ ID NO:2, CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-

IL-13 antibody comprises an L240A mutation. In some examples, the anti-IL-13 antibody comprises an L241A mutation. In some examples, the anti-IL-13 antibody comprises an L240A mutation and L241A mutation. In some examples, the anti-IL-13 antibody is cendakimab. In some examples, the anti-IL-13 antibody is administered subcutaneously.

5 In some examples, the anti-IL-13 antibody is administered at a dosage of about 100 mg to about 1000 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 200 mg to about 900 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 300 mg to about 800 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 360 mg to
10 about 720 mg to the subject. In some examples, the atopic dermatitis is a moderate atopic dermatitis. In some examples, the atopic dermatitis is a severe atopic dermatitis. In some examples, the atopic dermatitis is a moderate to severe atopic dermatitis.

An additional example is for a method of treating or ameliorating at least one symptom or indication of atopic dermatitis comprising administering to a subject in need
15 thereof a therapeutically effective amount of an anti-IL-13 antibody, or antigen binding fragment thereof, thereby treating or ameliorating the at least one symptom in the subject, wherein the at least one symptom is pruritus; dry skin; itching; red to brownish-gray patches of skin; small, raised bumps which that leak fluid and crust over when scratched; thickened skin; cracked skin; scaly skin; raw skin; skin sensitivity; or swollen skin. In some examples,
20 the anti-IL-13 antibody comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein the anti-IL-13 antibody comprises at least one of: (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2; (b) CDR-H2 comprising residues 52-67 of SEQ ID NO:2; (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2; (d) CDR-L1 comprising residues 24-34 of SEQ ID NO:3; (e) CDR-L2
25 comprising residues 50-56 of SEQ ID NO:3; or (f) CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, and CDR-H3 comprising residues 100-112 of SEQ ID NO:2. In some examples, the anti-IL-13

antibody comprises CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises CDR-H1 comprising residues 31-37 of SEQ ID NO:2, CDR-H2 comprising residues 52-67 of SEQ ID NO:2, CDR-H3 comprising residues 100-112 of SEQ ID NO:2, CDR-L1 comprising residues 24-34 of SEQ ID NO:3, CDR-L2 comprising residues 50-56 of SEQ ID NO:3, and CDR-L3 comprising residues 89-97 of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2. In some examples, the anti-IL-13 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3. In some examples, the anti-IL-13 antibody comprises an L240A mutation. In some examples, the anti-IL-13 antibody comprises an L241A mutation. In some examples, the anti-IL-13 antibody comprises an L240A mutation and L241A mutation. In some examples, the anti-IL-13 antibody is cendakimab. In some examples, the anti-IL-13 antibody is administered subcutaneously. In some examples, the anti-IL-13 antibody is administered at a dosage of about 100 mg to about 1000 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 200 mg to about 900 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 300 mg to about 800 mg to the subject. In some examples, the anti-IL-13 antibody is administered at a dosage of about 360 mg to about 720 mg to the subject. In some examples, the atopic dermatitis is a moderate atopic dermatitis. In some examples, the atopic dermatitis is a severe atopic dermatitis. In some examples, the atopic dermatitis is a moderate to severe atopic dermatitis.

Other objects and advantages will become apparent to those skilled in the art upon reference to the detailed description that hereinafter follows.

DETAILED DESCRIPTION

We claim:

1. An anti-IL-13 antibody, or antigen binding fragment thereof, for use in therapy, wherein the anti-IL-13 antibody, or antigen binding fragment thereof, comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3,
 - (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2;
 - (b) CDR-H2 comprising residues 52-67 of SEQ ID NO:2;
 - (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2;
 - (d) CDR-L1 comprising residues 24-34 of SEQ ID NO:3;
 - (e) CDR-L2 comprising residues 50-56 of SEQ ID NO:3; and
 - (f) CDR-L3 comprising residues 89-97 of SEQ ID NO:3.
2. The anti-IL-13 antibody for use of claim 1, wherein the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2.
3. The anti-IL-13 antibody for use of claim 1, wherein the anti-IL-13 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3.
4. The anti-IL-13 antibody for use of any one of claims 1-3, wherein the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3.
5. The anti-IL-13 antibody for use of any one of claims 1-4, wherein the anti-IL-13 antibody comprises an L240A mutation.
6. The anti-IL-13 antibody for use of any one of claims 1-4, wherein the anti-IL-13 antibody comprises an L241A mutation.

7. The anti-IL-13 antibody for use of any one of claims 1-6, wherein the anti-IL-13 antibody comprises an L240A mutation and L241A mutation.
8. The anti-IL-13 antibody for use of any one of claims 1-7, wherein the anti-IL-13 antibody is cendakimab.
9. The anti-IL-13 antibody for use of any one of claims 1-8, wherein the anti-IL-13 antibody is formulated for subcutaneous administration.
10. The anti-IL-13 antibody for use of any one of claims 1-9, wherein the anti-IL-13 antibody is formulated for a dosage of 100 mg to 1000 mg.
11. The anti-IL-13 antibody for use of any one of claims 1-10, wherein the anti-IL-13 antibody is formulated for a dosage of 200 mg to 900 mg.
12. The anti-IL-13 antibody for use of any one of claims 1-11, wherein the anti-IL-13 antibody is formulated for a dosage of 300 mg to 800 mg to the subject.
13. The anti-IL-13 antibody for use of any one of claims 1-12, wherein the anti-IL-13 antibody is formulated for a dosage of 360 mg to 720 mg to the subject.
14. Use of an anti-IL-13 antibody, or antigen binding fragment thereof, in the manufacture of a medicament for the treatment of atopic dermatitis, wherein the anti-IL-13 antibody, or antigen binding fragment thereof, comprises an antigen binding domain comprising six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3,
 - (a) CDR-H1 comprising residues 31-37 of SEQ ID NO:2;
 - (b) CDR-H2 comprising residues 52-67 of SEQ ID NO:2;
 - (c) CDR-H3 comprising residues 100-112 of SEQ ID NO:2;
 - (d) CDR-L1 comprising residues 24-34 of SEQ ID NO:3;
 - (e) CDR-L2 comprising residues 50-56 of SEQ ID NO:3; and
 - (f) CDR-L3 comprising residues 89-97 of SEQ ID NO:3.

15. The use of claim 14, wherein the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2.
16. The use of claim 14, wherein the anti-IL-13 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3.
17. The use of any one of claims 14-16, wherein the anti-IL-13 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:2 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:3.
18. The use of any one of claims 14-17, wherein the anti-IL-13 antibody comprises an L240A mutation.
19. The use of any one of claims 14-17, wherein the anti-IL-13 antibody comprises an L241A mutation.
20. The use of any one of claims 14-19, wherein the anti-IL-13 antibody comprises an L240A mutation and L241A mutation.
21. The use of any one of claims 14-20, wherein the anti-IL-13 antibody is cendakimab.
22. The use of any one of claims 14-21, wherein the anti-IL-13 antibody is formulated for subcutaneous administration.
23. The use of any one of claims 14-22, wherein the anti-IL-13 antibody is formulated for a dosage of 100 mg to 1000 mg.
24. The use of any one of claims 14-23, wherein the anti-IL-13 antibody is formulated for a dosage of 200 mg to 900 mg.

25. The use of any one of claims 14-24, wherein the anti-IL-13 antibody is formulated for a dosage of 300 mg to 800 mg.

26. The use of any one of claims 14-25, wherein the anti-IL-13 antibody is formulated for a dosage of 360 mg to 720 mg to the subject.

27. The use of any one of claims 14-26, wherein the atopic dermatitis is a moderate atopic dermatitis.

28. The use of any one of claims 14-26, wherein the atopic dermatitis is a severe atopic dermatitis.

29. The use of any one of claims 14-26, wherein the atopic dermatitis is a moderate to severe atopic dermatitis.